Suppr超能文献

一项关于以瓣膜进行抗反流黏膜成形术作为胃食管反流病新型内镜治疗方法的初步研究。

A pilot study on anti-reflux mucoplasty with valve as novel endoscopic therapy for gastroesophageal reflux disease.

作者信息

Yamamoto Kazuki, Inoue Haruhiro, Tanaka Ippei, Miyake Rei, Saino Masachika, Ushikubo Kei, Iwasaki Miyuki, Nishikawa Yohei, Abiko Satoshi, Gantuya Boldbaatar, Onimaru Manabu, Tanabe Mayo

机构信息

Digestive Diseases Center Showa University Koto Toyosu Hospital Tokyo Japan.

Department of Gastroenterology Mongolian National University of Medical Sciences Ulaanbaatar Mongolia.

出版信息

DEN Open. 2025 May 4;6(1):e70131. doi: 10.1002/deo2.70131. eCollection 2026 Apr.

Abstract

BACKGROUND AND AIMS

Endoscopic anti-reflux therapies like anti-reflux mucosectomy (ARMS) and anti-reflux mucosal ablation have shown efficacy for gastroesophageal reflux disease (GERD) in systematic reviews and meta-analyses. Anti-reflux mucoplasty (ARM-P), a refinement of ARMS, incorporates immediate closure of the resection site to reduce complications. Recently, anti-reflux mucosal valvuloplasty (ARMV), which employs endoscopic submucosal dissection to create a mucosal valve, was introduced but retains ARMS's limitations, requiring extensive incisions (three-quarters to four-fifths circumference). To address these challenges, we developed anti-reflux mucoplasty with valve (ARM-P/V), integrating ARMV's valvuloplasty with ARM-P's closure technique to improve safety and reduce complications. This pilot study evaluates the safety, feasibility, and efficacy of ARM-P/V.

METHODS

This retrospective study reviewed data from patients undergoing ARM-P/V for proton pump inhibitor (PPI)-refractory or PPI-dependent GERD at Showa University Koto Toyosu Hospital, Tokyo, from April to August 2024. Symptom severity and quality of life were assessed using validated questionnaires (GERD-Health Related Quality of Life Questionnaire [GERD-HRQL], GERD Questionnaire [GerdQ], and Frequency Scale for the Symptoms of GERD [FSSG]), comparing pre- and post-treatment scores. PPI discontinuation rates were also analyzed.

RESULTS

Eighteen patients (mean age 55.4 years) underwent ARM-P/V. Within 3 months, 72.2% (13/18) reduced or discontinued PPI use. GERD-HRQL scores improved from 20.3 to 10.9 ( = 0.004), GerdQ from 10.4 to 6.9 ( < 0.001), and FSSG from 24.0 to 13.2 ( < 0.001). No severe complications (Clavien-Dindo Grade ≥3), delayed bleeding or dysphagia requiring balloon dilation were reported.

CONCLUSIONS

ARM-P/V demonstrates safety, technical feasibility, and short-term efficacy in GERD treatment. As a refinement of ARMV, it offers a promising alternative to current techniques.

摘要

背景与目的

在系统评价和荟萃分析中,内镜抗反流治疗如抗反流黏膜切除术(ARMS)和抗反流黏膜消融术已显示出对胃食管反流病(GERD)的疗效。抗反流黏膜成形术(ARM-P)是ARMS的改良术式,它包括立即封闭切除部位以减少并发症。最近,引入了抗反流黏膜瓣膜成形术(ARMV),该术式采用内镜黏膜下剥离术创建黏膜瓣膜,但仍保留了ARMS的局限性,需要广泛的切口(圆周的四分之三至五分之四)。为应对这些挑战,我们开发了带瓣膜的抗反流黏膜成形术(ARM-P/V),将ARMV的瓣膜成形术与ARM-P的封闭技术相结合,以提高安全性并减少并发症。这项前瞻性研究评估了ARM-P/V的安全性、可行性和疗效。

方法

这项回顾性研究回顾了2024年4月至8月在东京昭和大学江东丰洲医院接受ARM-P/V治疗的质子泵抑制剂(PPI)难治性或PPI依赖性GERD患者的数据。使用经过验证的问卷(GERD健康相关生活质量问卷[GERD-HRQL]、GERD问卷[GerdQ]和GERD症状频率量表[FSSG])评估症状严重程度和生活质量,比较治疗前后的评分。还分析了PPI停药率。

结果

18例患者(平均年龄55.4岁)接受了ARM-P/V治疗。在3个月内,72.2%(13/18)的患者减少或停用了PPI。GERD-HRQL评分从20.3提高到10.9(P = 0.004),GerdQ评分从10.4提高到6.9(P < 0.001),FSSG评分从24.0提高到13.2(P < 0.001)。未报告严重并发症(Clavien-Dindo分级≥3级)、延迟出血或需要球囊扩张的吞咽困难。

结论

ARM-P/V在GERD治疗中显示出安全性、技术可行性和短期疗效。作为ARMV的改良术式,它为当前技术提供了一种有前景的替代方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2eb5/12050175/d751d658747b/DEO2-6-e70131-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验